Photo from wikipedia
Herein we describe a case of microangiopathic antiphospholipid syndrome (MAPS) due to anti‐phosphatidylserine/prothrombin complex (aPS/PT) IgM antibody successfully treated with rituximab. A significant correlation was observed between the clinical course… Click to show full abstract
Herein we describe a case of microangiopathic antiphospholipid syndrome (MAPS) due to anti‐phosphatidylserine/prothrombin complex (aPS/PT) IgM antibody successfully treated with rituximab. A significant correlation was observed between the clinical course and the aPS/PT IgM antibody titer, which can rise earlier before the appearance of clinical symptoms. Rituximab can be safely and effectively used for MAPS. Although detection of only aPS/PT IgM antibody is rare, aPS/PT IgM antibody might be associated with the pathogenesis of MAPS and might be a useful marker of disease activity.
Journal Title: Pediatrics International
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!